Recent results have cast doubt over how effective a breakthrough class of cystic fibrosis drugs can be in patients with the most common form of the disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Holmes, D. False dawn for cystic fibrosis disease modifiers?. Nat Rev Drug Discov 13, 713–714 (2014). https://doi.org/10.1038/nrd4456
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4456
This article is cited by
-
Vertex combo scores a broader cystic fibrosis approval
Nature Reviews Drug Discovery (2015)